Arcutis EVP sells 2,052 shares for tax withholding

Arcutis Biotherapeutics executive Larry Todd Edwards reported a small insider sale of common stock.

Rhea-AI Filing Summary

Arcutis Biotherapeutics executive Larry Todd Edwards reported a small insider sale of common stock. On February 2, 2026, he sold 2,052 shares at a weighted average price of $25.4984 per share, solely to cover tax withholding obligations from vesting restricted stock units (RSUs).

The RSUs were granted on January 12, 2024 and vest 25% annually each February 1, beginning in 2025, subject to continued service. After this tax-related sale, Edwards beneficially owns 148,865 shares, including 724 shares purchased under the company’s Employee Stock Purchase Plan on November 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction does the latest Arcutis (ARQT) Form 4 report?

The filing reports that EVP Chief Commercial Officer Larry Todd Edwards sold 2,052 Arcutis shares on February 2, 2026. The shares were sold at a weighted average price of $25.4984 per share, according to the reported transaction details.

Why did Arcutis executive Larry Todd Edwards sell 2,052 shares of ARQT stock?

The sale of 2,052 shares was made to cover tax withholding obligations related to the vesting of restricted stock units granted on January 12, 2024. This indicates the transaction was tax-driven rather than a discretionary open-market sale.

How many Arcutis (ARQT) shares does Larry Todd Edwards own after this Form 4 transaction?

After the reported sale, Larry Todd Edwards beneficially owns 148,865 Arcutis shares. This total includes 724 shares that were purchased through Arcutis Biotherapeutics’ Employee Stock Purchase Plan on November 30, 2025, as disclosed in the filing.

What are the vesting terms of the RSUs linked to the Arcutis (ARQT) insider sale?

The RSUs were granted on January 12, 2024. Twenty-five percent of the RSUs vest annually on February 1 of each year, starting on February 1, 2025, and vesting is conditioned on continued service to Arcutis Biotherapeutics.

What price range is associated with the 2,052 ARQT shares sold in this Form 4?

The Form 4 reports a weighted average sale price of $25.4984 per share. The 2,052 shares were sold in multiple trades at prices ranging from $24.745 to $25.68, and detailed trade breakdowns are available on request from the reporting person.

Who is the reporting person in the Arcutis (ARQT) Form 4 and what is their role?

The reporting person is Larry Todd Edwards, identified with the title EVP Chief Commercial Officer of Arcutis Biotherapeutics, Inc. The Form 4 is signed by Latha Vairavan acting as Attorney-in-Fact for Larry Todd Edwards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 07:21 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edwards Larry Todd

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		2,052	D	$25.4984(2)	148,865(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligation in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.745 to $25.68, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on November 30, 2025.

Remarks:

Reporting Person's title: EVP Chief Commercial Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Larry Todd Edwards	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.